Aptose Announces Positive Decision by Nasdaq Hearings Panel
19. Dezember 2024 16:05 ET
|
Aptose Biosciences, Inc.
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
09. Dezember 2024 12:00 ET
|
Aptose Biosciences, Inc.
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
03. Dezember 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
25. November 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
20. November 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Reports Results for the Third Quarter 2024
08. November 2024 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
05. September 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30. August 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
15. August 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
08. August 2024 17:06 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Second Quarter 2024